NO20053467L - Fremgangsmate ved biotransformasjon av kolkionforbindelser til de tilsvarende 3-glykosyl-derivater - Google Patents

Fremgangsmate ved biotransformasjon av kolkionforbindelser til de tilsvarende 3-glykosyl-derivater

Info

Publication number
NO20053467L
NO20053467L NO20053467A NO20053467A NO20053467L NO 20053467 L NO20053467 L NO 20053467L NO 20053467 A NO20053467 A NO 20053467A NO 20053467 A NO20053467 A NO 20053467A NO 20053467 L NO20053467 L NO 20053467L
Authority
NO
Norway
Prior art keywords
biotransformation
pharmaceutically acceptable
glycosyl derivatives
pharmaceutical
carbonic compounds
Prior art date
Application number
NO20053467A
Other languages
English (en)
Norwegian (no)
Inventor
Tsuyoshi Naganuma
Mitsuo Muramatsu
Original Assignee
Kissei Pharmaceutical Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32588229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20053467(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kissei Pharmaceutical Company filed Critical Kissei Pharmaceutical Company
Publication of NO20053467L publication Critical patent/NO20053467L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20053467A 2002-12-16 2005-07-15 Fremgangsmate ved biotransformasjon av kolkionforbindelser til de tilsvarende 3-glykosyl-derivater NO20053467L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002364238 2002-12-16
PCT/JP2003/015837 WO2004054574A1 (fr) 2002-12-16 2003-12-11 Medicament solide administre par voie orale

Publications (1)

Publication Number Publication Date
NO20053467L true NO20053467L (no) 2005-07-15

Family

ID=32588229

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053467A NO20053467L (no) 2002-12-16 2005-07-15 Fremgangsmate ved biotransformasjon av kolkionforbindelser til de tilsvarende 3-glykosyl-derivater

Country Status (23)

Country Link
US (2) US20060018959A1 (fr)
EP (2) EP1574215B1 (fr)
JP (1) JP4633469B2 (fr)
KR (2) KR101077061B1 (fr)
CN (2) CN101069685B (fr)
AU (1) AU2003289320C1 (fr)
BR (1) BR0317349A (fr)
CA (1) CA2507002C (fr)
EA (1) EA008196B1 (fr)
ES (1) ES2544560T3 (fr)
HR (1) HRP20050544B1 (fr)
IL (1) IL169040A (fr)
IS (1) IS7929A (fr)
ME (2) MEP10808A (fr)
MX (1) MXPA05006513A (fr)
NO (1) NO20053467L (fr)
NZ (1) NZ540664A (fr)
PL (1) PL220457B1 (fr)
RS (1) RS58025B1 (fr)
TW (2) TWI325318B (fr)
UA (2) UA85359C2 (fr)
WO (1) WO2004054574A1 (fr)
ZA (1) ZA200504613B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085195A1 (fr) 2004-03-05 2005-09-15 Kissei Pharmaceutical Co., Ltd. Composition thérapeutique destinée à prévenir ou à traiter une vessie hyperactive qui accompagne un trouble nerveux
WO2006038611A1 (fr) * 2004-10-05 2006-04-13 Kissei Pharmaceutical Co., Ltd. Agent pour le traitement prophylactique ou thérapeutique des troubles de collecte de l'urine dans la vessie consécutifs à l'obstruction du canal urinaire inférieur
WO2008106536A1 (fr) * 2007-02-28 2008-09-04 Kissei Pharmaceuticals Co., Ltd. Utilisation de silodosine administrée une fois par jour pour le traitement d'une hyperplasie prostatique bénigne
CL2008000727A1 (es) * 2007-03-13 2008-10-17 Takeda Pharmaceutical Granulo compuesto por 2-[[6-[(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-4-fluorobenzonitrilo o una de sus sales y un aditivo que no comprende celulosa microcristalina; preparacion solida; comprimido y procedimi
JP5965902B2 (ja) 2010-06-28 2016-08-10 ラティオファルム ゲー・エム・ベー・ハー シロドシン−シクロデキストリン包接化合物
EP2595607A2 (fr) 2010-07-23 2013-05-29 Ratiopharm GmbH Médicament d'administration orale contenant un mélange de silodosine et d'un copolymère basique
PL2474529T3 (pl) 2010-12-23 2014-10-31 Sandoz Ag Formy krystaliczne farmaceutycznej substancji czynnej
CN102283816B (zh) * 2011-08-05 2013-09-11 北京海步国际医药科技发展有限公司 西洛多辛缓释片剂及其制备方法
US20140243383A1 (en) * 2011-08-24 2014-08-28 Cadila Healthcare Limited Pharmaceutical compositions of silodosin
JP6031722B2 (ja) * 2011-08-31 2016-11-24 国立大学法人 千葉大学 女性の排尿障害の治療剤
AR090073A1 (es) * 2012-02-16 2014-10-15 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
KR102318720B1 (ko) 2012-07-16 2021-10-28 피브로겐, 인크. 프롤릴 하이드록실라제 억제제 [(4-하이드록시-1-메틸-7-페녹시-아이소퀴놀린-3-카보닐)-아미노]-아세트산의 결정형
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
WO2014157137A1 (fr) 2013-03-26 2014-10-02 キッセイ薬品工業株式会社 Préparation pour l'administration orale avec l'amertume de la silodosine masquée
KR102291860B1 (ko) 2013-06-06 2021-08-20 피브로겐, 인크. Hif 하이드록실라제 억제자의 약학적 제형
KR102206104B1 (ko) * 2014-04-03 2021-01-22 한미약품 주식회사 실로도신을 포함하는 과립물, 및 이를 포함하는 약학적 조성물 및 제형
CN103933001A (zh) * 2014-05-09 2014-07-23 浙江华海药业股份有限公司 一种稳定的赛洛多辛口服固体药物组合物及其制备方法
CN105435233B (zh) * 2014-08-06 2018-05-01 江苏正大丰海制药有限公司 一种英加韦林的药物组合物
JP6366547B2 (ja) * 2015-08-03 2018-08-01 大原薬品工業株式会社 光安定性が向上した、プラミペキソール製剤包装体
CN108685867A (zh) * 2017-04-06 2018-10-23 昆明积大制药股份有限公司 一种赛洛多辛薄膜衣片及其制备方法
EP3354283B1 (fr) 2017-06-20 2019-08-07 Alfred E. Tiefenbacher (GmbH & Co. KG) Composition de capsule pharmaceutique comprenant de la silodosine
CN111437260A (zh) * 2019-01-17 2020-07-24 北京万全德众医药生物技术有限公司 用于制备盐酸美金刚固态药物组合物的方法
JP7262005B2 (ja) * 2019-01-25 2023-04-21 日本ジェネリック株式会社 シロドシン含有固形組成物及びその製造法
CN114601826B (zh) * 2022-03-31 2024-06-04 乐泰药业有限公司 一种用于治疗前列腺增生的药物制剂及其制备方法和质量检测方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1060073A (en) 1963-03-02 1967-02-22 Benger Lab Ltd 2,2,2-trichlorethyl hydrogen succinate and salts
US4547498A (en) 1983-01-06 1985-10-15 Mylan Pharmaceuticals Inc. Pharmaceutical combination composition and associated method
US4757090A (en) * 1986-07-14 1988-07-12 Mallinckrodt, Inc. Direct tableting acetaminophen compositions
HU200926B (en) * 1988-10-28 1990-09-28 Egyt Gyogyszervegyeszeti Gyar Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules
EP0600675B1 (fr) * 1992-12-02 1998-07-08 Kissei Pharmaceutical Co., Ltd. Composés indoliniques pour le traitement de la dysurien
US5370878A (en) * 1993-09-30 1994-12-06 Hallmark Pharmaceuticals, Inc. Method for preparing a direct compression granulated acetaminophen composition
JP2977907B2 (ja) 1994-05-06 1999-11-15 ファイザー・インコーポレーテッド アジスロマイシンの放出調節された剤形
ES2125198B1 (es) * 1997-05-13 1999-11-16 Vita Invest Sa Asociacion a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y su utilizacion para el tratamiento de enfermees cardiovasculares.
AR016827A1 (es) 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
WO1999015202A1 (fr) * 1997-09-22 1999-04-01 Kissei Pharmaceutical Co., Ltd. Medicaments contre la dysurie resultant d'une hypertrophie de la prostate
US20020177593A1 (en) * 1998-09-30 2002-11-28 Yuji Ishihara Agents and crystals for improving excretory potency of urinary bladder
JP4324266B2 (ja) 1999-02-26 2009-09-02 キッセイ薬品工業株式会社 α１Ａアドレナリン受容体の変異体、当該変異体を用いた測定方法及び前立腺肥大に伴う排尿困難症治療剤
US20010053780A1 (en) 1999-04-30 2001-12-20 Whitaker John S. Daily treatment for erectile dysfunction using a PDE5 inhibitor
JP4014068B2 (ja) * 1999-07-28 2007-11-28 芦森工業株式会社 エアバッグ装置
PE20011178A1 (es) * 2000-04-07 2001-11-19 Takeda Chemical Industries Ltd Compuestos heterociclicos y su produccion
EP1293206A4 (fr) 2000-05-15 2005-09-21 Kissei Pharmaceutical Preparation liquide a base d'eau
ES2274013T3 (es) * 2001-01-26 2007-05-16 Schering Corporation Combinaciones de activador(es) del receptor activado por el proliferador de los peroxisomas (ppar) e inhibidor(es)m de la absorcion de estelores y tratamientos para trastornos vasculares.
JP2001288115A (ja) 2001-02-07 2001-10-16 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
JPWO2002069957A1 (ja) * 2001-03-01 2004-07-02 グレラン製薬株式会社 フェノフィブラート含有組成物
US6786714B2 (en) * 2001-04-12 2004-09-07 James W. Haskew Delivery system for liquid catalysts
GB0113843D0 (en) 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
UA78854C2 (en) * 2002-09-06 2007-04-25 Kissei Pharmaceutical Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same

Also Published As

Publication number Publication date
RS20050470A (sr) 2007-09-21
CA2507002A1 (fr) 2004-07-01
BR0317349A (pt) 2005-11-16
MXPA05006513A (es) 2005-09-08
TW200418457A (en) 2004-10-01
TWI382838B (zh) 2013-01-21
ZA200504613B (en) 2006-08-30
EA200500985A1 (ru) 2005-12-29
MEP10808A (en) 2010-06-10
CN100339078C (zh) 2007-09-26
ES2544560T3 (es) 2015-09-01
CA2507002C (fr) 2012-09-18
PL220457B1 (pl) 2015-10-30
HK1107768A1 (en) 2008-04-18
ME00076B (me) 2011-02-10
HK1085131A1 (en) 2006-08-18
AU2003289320C1 (en) 2018-09-06
IS7929A (is) 2005-07-01
PL377495A1 (pl) 2006-02-06
US20120064154A1 (en) 2012-03-15
KR20050084316A (ko) 2005-08-26
AU2003289320B2 (en) 2008-08-21
US20060018959A1 (en) 2006-01-26
AU2003289320A1 (en) 2004-07-09
KR101072909B1 (ko) 2011-10-17
HRP20050544A2 (en) 2006-09-30
EP2402010A1 (fr) 2012-01-04
CN1726028A (zh) 2006-01-25
HRP20050544B1 (hr) 2017-12-01
NZ540664A (en) 2007-09-28
JPWO2004054574A1 (ja) 2006-04-20
EA008196B1 (ru) 2007-04-27
CN101069685B (zh) 2011-12-14
RS58025B1 (sr) 2019-02-28
EP1574215A1 (fr) 2005-09-14
WO2004054574A1 (fr) 2004-07-01
JP4633469B2 (ja) 2011-02-16
UA84694C2 (ru) 2008-11-25
TW200944200A (en) 2009-11-01
KR20100133024A (ko) 2010-12-20
EP1574215B1 (fr) 2015-07-15
IL169040A (en) 2013-04-30
KR101077061B1 (ko) 2011-10-26
TWI325318B (en) 2010-06-01
UA85359C2 (ru) 2009-01-12
CN101069685A (zh) 2007-11-14
EP1574215A4 (fr) 2009-07-01

Similar Documents

Publication Publication Date Title
NO20053467L (no) Fremgangsmate ved biotransformasjon av kolkionforbindelser til de tilsvarende 3-glykosyl-derivater
AU2001271741B2 (en) Pharmaceutical compositions of estrogenic agents
NO20050397L (no) Tricykliske steroidhormonnukleaere reseptormodulatorer
RU2006109467A (ru) Способы лечения рака с использованием ингибиторов hdac
NO20045072L (no) Tablett med hoyt medikamentinnhold
RU2005115855A (ru) Композиция трамадола продлонгированного высвобождением с 24-часовым действием
NO20073465L (no) Benzotiazol-derivater
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
NO20082643L (no) Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
EP3291815A1 (fr) Méthodes de traitement d'une maladie neurodégénérative
NO20052130L (no) Sterk inhibitor for HCV-serin-protease
RU2010107843A (ru) Бупропиона гидробромид и его терапевтические применения
NO20062004L (no) Forlenget frigjoring farmasoytiske blandinger omfattene aplindor og derivater derav
NO20080697L (no) Modifiserte farmasoytiske doseringsformer for frigivelse av syklooksygenase enzyminhibitor
RU2000122435A (ru) Производные индола и фармацевтические композиции, включающие их
HUT71329A (en) Pharmaceutical compositions for inhibiting cns problems in post-menopausal women containing 2-phenyl-3-aroyl-benzothiophene-derivatives and process for their preparation
NO20051901L (no) Nye antimycobakterielle sammensetninger og pyrrole derivater som antimycobakterielle sammensetninger
NO20044091L (no) Anvendelse av substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on for fremstilling av medikamenter som inhiberer pankreatisk lipase
JP2004538289A5 (fr)
HUP0004900A2 (hu) Mozgászavarok kezelésére szolgáló, hatóanyagként NMDA-receptor antagonista hatású piperidinszármazékokat tartalmazó gyógyszerkészítmények
JP5386478B2 (ja) パーキンソン病に伴う運動不全の治療のための４−シクロプロピルメトキシ−ｎ−（３，５−ジクロロ−１−オキシドピリジン−４−イル）−５−（メトキシ）ピリジン−２−カルボキサミドの使用
JP3598116B2 (ja) 遅発性ジスキネジアの治療用医薬組成物とその利用
BR112013000164B1 (pt) Agente terapêutico ou agente profilático
NO20050903L (no) Nye piperazinyl-pyrazinonderivater for behandling av 5HT-2A reseptorrelaterte forstyrrelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application